---
title: "Raffles Medical: More time needed to generate strong returns due to poor performance in China | Lianhe Zaobao"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283257926.md"
description: "Raffles Medical Group stated at the shareholders' meeting that its performance in China has been poor and requires more time to achieve significant returns. Although the China business accounts for 30% of the group's assets, it only contributes 10% of the revenue. The group pointed out that overseas investments typically take longer to scale and establish clinical capabilities, and the Chinese market is constrained by geopolitical and technological challenges. The Securities and Futures Commission believes that the China business has only increased revenue by approximately 25.4 million yuan over the past seven years, and it is expected to reach 65.4 million yuan by the fiscal year 2025"
datetime: "2026-04-19T14:42:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283257926.md)
  - [en](https://longbridge.com/en/news/283257926.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283257926.md)
---

# Raffles Medical: More time needed to generate strong returns due to poor performance in China | Lianhe Zaobao

As the performance of its China business is underwhelming, Raffles Medical Group pointed out that the group needs more time to generate substantial returns.

In response to questions from the Singapore Investor Association (SIAS) before the shareholders' meeting on Saturday (April 18), Raffles Medical Group noted that its China business accounts for 30% of the group's assets but only contributes 10% of revenue.

The group further stated that during overseas investments, it typically takes longer to establish scale, clinical capabilities, etc., to achieve stronger investment returns.

The group also mentioned that the Chinese market is constrained by geopolitical and technological challenges.

#### Further Reading

Raffles Medical Group's net profit increased by 21.7% in the second half of last year

The investor association believes that the group's growth in China has been slow, with revenue increasing by only about SGD 25.4 million over the past seven years, reaching SGD 65.4 million in the fiscal year 2025. Meanwhile, the group's asset scale in Singapore is approximately 2.2 times that of its assets in China, but its revenue is 10.4 times higher.

The group emphasized that the Chinese market is very important, as about 30% of China's population can afford high-quality medical services.

The group added that it has been observing the liberalization and development of the private healthcare market in China for over 30 years before entering the market.

On Friday (April 17), the group closed at SGD 1.02, down 0.97%

### Related Stocks

- [BSL.SG](https://longbridge.com/en/quote/BSL.SG.md)

## Related News & Research

- [Raffles Medical CEO tightens grip with $0.99 share sweep](https://longbridge.com/en/news/280728726.md)
- [Undiscovered Gems in Europe for May 2026](https://longbridge.com/en/news/286722063.md)
- [Range Impact GAAP EPS of -$0.02, revenue of $0.92M](https://longbridge.com/en/news/286725496.md)
- [3 energy stocks that are quietly becoming the trades of the year](https://longbridge.com/en/news/286790976.md)
- [European Undervalued Small Caps With Insider Action For May 2026](https://longbridge.com/en/news/286721352.md)